COR
Cencora, Inc.
Price Chart
Latest Quote
$271.83
-5.26 (-1.90%)
Current Price
| Previous Close | $277.09 |
| Open | $276.96 |
| Day High | $278.79 |
| Day Low | $270.06 |
| Volume | 1,537,714 |
Stock Information
| Quarterly Dividend / Yield | $2.40 / 0.88% |
| Shares Outstanding | 194.56M |
| Quarterly Dividend Yield | 0.88% |
| Quarterly Dividend | $2.40 |
| Total Debt | $15.09B |
| Cash Equivalents | $2.18B |
| Revenue | $328.68B |
| Net Income | $2.55B |
| Sector | Healthcare |
| Industry | Medical Distribution |
| Market Cap | $52.89B |
| P/E Ratio | 20.83 |
| EPS (TTM) | $13.05 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $65.99B |
| Sales | $328.68B |
| Income | $2.55B |
| Book/sh | $17.46 |
| Cash/sh | $11.19 |
| Employees | 47K |
Financial Ratios
| Quick Ratio | 0.48 |
| Current Ratio | 0.95 |
| Debt/Eq | 420.99 |
| EPS Growth TTM | 128.60% |
Returns & Margins
| ROA | 3.49% |
| ROE | 107.13% |
| Gross Margin | 3.80% |
| Operating Margin | 1.72% |
| Profit Margin | 0.78% |
Ownership
| Insider Ownership | 4.23% |
| Institutional Ownership | 98.76% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 13.74 |
| PEG | 0.58 |
| P/S | 0.16 |
| P/B | 15.57 |
Analyst Data
| Recommendation | buy |
| Target Price | $350.58 |
Technical Indicators
| SMA20 | $273.18 |
| SMA50 | $285.43 |
| SMA200 | $323.71 |
| RSI | 53.44 |
| ATR | 6.1071 |
| Shares Float | 184.01M |
| Short Float | 3.22% |
| Short Ratio | 2.36 |
| Volatility | 0.59 |
| Rel Volume | 2.18 |
Performance History
| Week | -3.43% |
| Month | +2.13% |
| Quarter | -17.87% |
| 6 Months | -20.13% |
| YTD | -19.46% |
| Year | -6.59% |
| 3 Years | +55.14% |
| 5 Years | +146.75% |
| 10 Years | +377.47% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $271.83 | 3,408,900 |
| 2026-06-17 | $277.09 | 1,466,300 |
| 2026-06-16 | $281.46 | 1,013,500 |
| 2026-06-15 | $281.43 | 1,818,000 |
| 2026-06-12 | $281.67 | 1,061,900 |
| 2026-06-11 | $281.48 | 938,300 |
| 2026-06-10 | $281.24 | 977,800 |
| 2026-06-09 | $279.57 | 1,282,200 |
| 2026-06-08 | $274.08 | 893,900 |
| 2026-06-05 | $275.04 | 1,319,200 |
| 2026-06-04 | $270.32 | 1,498,000 |
| 2026-06-03 | $263.64 | 1,592,400 |
| 2026-06-02 | $264.84 | 1,477,100 |
| 2026-06-01 | $264.69 | 1,625,800 |
| 2026-05-29 | $269.36 | 3,105,100 |
| 2026-05-28 | $267.71 | 1,486,500 |
| 2026-05-27 | $267.01 | 1,459,100 |
| 2026-05-26 | $270.78 | 1,343,200 |
| 2026-05-22 | $274.91 | 2,144,700 |
| 2026-05-21 | $265.44 | 1,300,700 |
| 2026-05-20 | $264.75 | 1,943,200 |
| 2026-05-19 | $266.17 | 1,813,000 |
About Cencora, Inc.
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
đ° Latest News
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?
Motley Fool âĸ 2026-06-19T17:10:34Z
CAH Stock Up Nearly 8% YTD: Will the Uptrend Continue in the Rest of 2026?
Zacks âĸ 2026-06-19T12:36:00Z
COR Stock Down Nearly 18% YTD: Should You Buy, Hold or Sell?
Zacks âĸ 2026-06-18T16:49:00Z
Cencora Launches Enhanced Nucleus Solution for Specialty Practices
Zacks âĸ 2026-06-18T14:33:00Z
Bet on 5 Top-Ranked Stocks With Rising P/E for Solid Returns
Zacks âĸ 2026-06-18T12:00:00Z
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
Zacks âĸ 2026-06-17T12:55:00Z
Cardinal Health Stock: Is CAH Outperforming the Healthcare Sector?
Barchart âĸ 2026-06-15T15:47:26Z
Assessing Cencora (COR) Valuation After Kite CAR T Distribution Deal And Upcoming CFO Transition
Simply Wall St. âĸ 2026-06-10T16:13:51Z
Cencora Kite Deal Highlights CAR T Growth And Undervalued Share Price Potential
Simply Wall St. âĸ 2026-06-10T14:05:45Z
2 Dirt Cheap Healthcare Stocks to Buy With $1,000 Right Now
Motley Fool âĸ 2026-06-09T15:05:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $309,836,939,000 | $284,021,702,000 | $253,196,974,000 | $230,274,699,000 |
| Cost Of Revenue | $309,854,280,000 | $284,048,570,000 | $253,213,918,000 | $230,290,639,000 |
| Total Revenue | $321,332,819,000 | $293,958,599,000 | $262,173,411,000 | $238,587,006,000 |
| Operating Revenue | $321,332,819,000 | $293,958,599,000 | $262,173,411,000 | $238,587,006,000 |
| Expenses | ||||
| Interest Expense | $419,753,000 | $248,682,000 | $228,931,000 | $210,673,000 |
| Total Expenses | $317,399,197,000 | $290,801,650,000 | $259,487,806,000 | $235,833,496,000 |
| Other Income Expense | $-1,383,738,000 | $-995,983,000 | $-295,838,000 | $-359,780,000 |
| Other Non Operating Income Expenses | $-78,717,000 | $-14,283,000 | $49,036,000 | $27,352,000 |
| Net Non Operating Interest Income Expense | $-291,548,000 | $-156,991,000 | $-228,931,000 | $-210,673,000 |
| Interest Expense Non Operating | $419,753,000 | $248,682,000 | $228,931,000 | $210,673,000 |
| Operating Expense | $7,544,917,000 | $6,753,080,000 | $6,273,888,000 | $5,542,857,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $1,554,169,000 | $1,509,120,000 | $1,745,293,000 | $1,698,820,000 |
| Net Interest Income | $-291,548,000 | $-156,991,000 | $-228,931,000 | $-210,673,000 |
| Interest Income | $128,205,000 | $91,691,000 | $46,719,000 | $21,309,000 |
| Normalized Income | $2,460,159,160 | $2,253,375,943 | $2,021,881,948 | $1,994,201,716 |
| Net Income From Continuing And Discontinued Operation | $1,554,169,000 | $1,509,120,000 | $1,745,293,000 | $1,698,820,000 |
| Total Operating Income As Reported | $2,628,601,000 | $2,175,249,000 | $2,340,731,000 | $2,366,378,000 |
| Net Income Common Stockholders | $1,554,169,000 | $1,509,120,000 | $1,745,293,000 | $1,698,820,000 |
| Net Income | $1,554,169,000 | $1,509,120,000 | $1,745,293,000 | $1,698,820,000 |
| Net Income Including Noncontrolling Interests | $1,567,814,000 | $1,519,273,000 | $1,732,576,000 | $1,666,540,000 |
| Net Income Continuous Operations | $1,567,814,000 | $1,519,273,000 | $1,732,576,000 | $1,666,540,000 |
| Pretax Income | $2,258,336,000 | $2,003,975,000 | $2,160,836,000 | $2,183,057,000 |
| Special Income Charges | $-1,305,021,000 | $-981,700,000 | $-344,874,000 | $-387,132,000 |
| Interest Income Non Operating | $128,205,000 | $91,691,000 | $46,719,000 | $21,309,000 |
| Operating Income | $3,933,622,000 | $3,156,949,000 | $2,685,605,000 | $2,753,510,000 |
| Depreciation Amortization Depletion Income Statement | $1,051,075,000 | $1,091,974,000 | $963,904,000 | $693,895,000 |
| Depreciation And Amortization In Income Statement | $1,051,075,000 | $1,091,974,000 | $963,904,000 | $693,895,000 |
| Amortization Of Intangibles Income Statement | $556,934,000 | $663,474,000 | $553,563,000 | $307,300,000 |
| Depreciation Income Statement | $494,141,000 | $428,500,000 | $410,341,000 | $386,595,000 |
| Gross Profit | $11,478,539,000 | $9,910,029,000 | $8,959,493,000 | $8,296,367,000 |
| Per Share | ||||
| Diluted EPS | $7.96 | $7.53 | $8.53 | $8.04 |
| Basic EPS | $8.02 | $7.60 | $8.62 | $8.15 |
| Other | ||||
| Tax Effect Of Unusual Items | $-399,030,840 | $-237,444,057 | $-68,285,052 | $-91,750,284 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $5,051,526,000 | $4,353,199,000 | $3,715,489,000 | $3,490,697,000 |
| Total Unusual Items | $-1,305,021,000 | $-981,700,000 | $-344,874,000 | $-387,132,000 |
| Total Unusual Items Excluding Goodwill | $-1,305,021,000 | $-981,700,000 | $-344,874,000 | $-387,132,000 |
| Reconciled Depreciation | $1,068,416,000 | $1,118,842,000 | $980,848,000 | $709,835,000 |
| EBITDA (Bullshit earnings) | $3,746,505,000 | $3,371,499,000 | $3,370,615,000 | $3,103,565,000 |
| EBIT | $2,678,089,000 | $2,252,657,000 | $2,389,767,000 | $2,393,730,000 |
| Diluted Average Shares | $195,214,000 | $200,284,000 | $204,591,000 | $211,210,000 |
| Basic Average Shares | $193,820,000 | $198,503,000 | $202,511,000 | $208,472,000 |
| Diluted NI Availto Com Stockholders | $1,554,169,000 | $1,509,120,000 | $1,745,293,000 | $1,698,820,000 |
| Minority Interests | $-13,645,000 | $-10,153,000 | $12,717,000 | $32,280,000 |
| Tax Provision | $690,522,000 | $484,702,000 | $428,260,000 | $516,517,000 |
| Other Special Charges | $60,671,000 | $227,070,000 | $-24,693,000 | $123,191,000 |
| Impairment Of Capital Assets | $723,884,000 | $418,000,000 | $0 | $75,936,000 |
| Restructuring And Mergern Acquisition | $520,466,000 | $336,630,000 | $369,567,000 | $183,059,000 |
| Amortization | $556,934,000 | $663,474,000 | $553,563,000 | $307,300,000 |
| Selling General And Administration | $6,493,842,000 | $5,661,106,000 | $5,309,984,000 | $4,848,962,000 |
| Write Off | - | $0 | $0 | $4,946,000 |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-15,942,682,000 | $-12,673,135,000 | $-13,483,897,000 | $-13,048,182,000 |
| Total Assets | $76,590,112,000 | $67,101,667,000 | $62,558,746,000 | $56,560,616,000 |
| Total Non Current Assets | $24,351,039,000 | $19,383,854,000 | $19,759,920,000 | $16,970,858,000 |
| Other Non Current Assets | $4,152,452,000 | $3,637,023,000 | $3,418,182,000 | $1,761,661,000 |
| Non Current Deferred Assets | $208,810,000 | $246,348,000 | $200,667,000 | $237,571,000 |
| Non Current Deferred Taxes Assets | $208,810,000 | $246,348,000 | $200,667,000 | $237,571,000 |
| Goodwill And Other Intangible Assets | $17,450,701,000 | $13,319,073,000 | $14,005,900,000 | $12,836,623,000 |
| Other Intangible Assets | $3,774,181,000 | $4,001,046,000 | $4,431,783,000 | $4,332,737,000 |
| Current Assets | $52,239,073,000 | $47,717,813,000 | $42,798,826,000 | $39,589,758,000 |
| Other Current Assets | $2,165,156,000 | $1,714,517,000 | $1,763,806,000 | $2,019,932,000 |
| Inventory | $20,492,480,000 | $18,998,833,000 | $17,454,768,000 | $15,556,394,000 |
| Receivables | $25,225,299,000 | $23,871,815,000 | $20,988,201,000 | $18,625,243,000 |
| Accounts Receivable | $25,225,299,000 | $23,871,815,000 | $20,911,081,000 | $18,452,675,000 |
| Allowance For Doubtful Accounts Receivable | $-1,796,172,000 | $-1,308,018,000 | $-1,433,396,000 | $-1,626,729,000 |
| Gross Accounts Receivable | $27,021,471,000 | $25,179,833,000 | $22,344,477,000 | $20,079,404,000 |
| Cash Cash Equivalents And Short Term Investments | $4,356,138,000 | $3,132,648,000 | $2,592,051,000 | $3,388,189,000 |
| Cash And Cash Equivalents | $4,356,138,000 | $3,132,648,000 | $2,592,051,000 | $3,388,189,000 |
| Taxes Receivable | - | $88,229,000 | $77,120,000 | $172,568,000 |
| Assets Held For Sale Current | - | - | - | $0 |
| Prepaid Assets | - | - | - | $487,871,000 |
| Debt | ||||
| Net Debt | $3,304,635,000 | $1,255,428,000 | $2,195,406,000 | $2,314,644,000 |
| Total Debt | $7,660,773,000 | $4,388,076,000 | $4,787,457,000 | $5,702,833,000 |
| Long Term Debt And Capital Lease Obligation | $7,542,988,000 | $3,811,745,000 | $4,146,113,000 | $4,632,360,000 |
| Long Term Debt | $7,542,988,000 | $3,811,745,000 | $4,146,113,000 | $4,632,360,000 |
| Current Debt And Capital Lease Obligation | $117,785,000 | $576,331,000 | $641,344,000 | $1,070,473,000 |
| Current Debt | $117,785,000 | $576,331,000 | $641,344,000 | $1,070,473,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $74,843,027,000 | $66,314,925,000 | $61,892,459,000 | $56,489,343,000 |
| Total Non Current Liabilities Net Minority Interest | $17,022,488,000 | $12,037,872,000 | $13,061,261,000 | $13,011,388,000 |
| Other Non Current Liabilities | $3,639,862,000 | $1,993,683,000 | $1,884,733,000 | $976,583,000 |
| Tradeand Other Payables Non Current | $337,631,000 | $291,796,000 | $310,676,000 | $320,274,000 |
| Non Current Deferred Liabilities | $1,620,724,000 | $1,643,746,000 | $1,657,944,000 | $1,620,413,000 |
| Non Current Deferred Taxes Liabilities | $1,620,724,000 | $1,643,746,000 | $1,657,944,000 | $1,620,413,000 |
| Current Liabilities | $57,820,539,000 | $54,277,053,000 | $48,831,198,000 | $43,477,955,000 |
| Payables And Accrued Expenses | $57,702,754,000 | $53,700,722,000 | $48,189,854,000 | $42,407,482,000 |
| Payables | $54,719,761,000 | $50,942,162,000 | $45,836,037,000 | $40,192,890,000 |
| Accounts Payable | $54,719,761,000 | $50,942,162,000 | $45,836,037,000 | $40,192,890,000 |
| Other Current Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $1,508,019,000 | $645,938,000 | $522,003,000 | $-211,559,000 |
| Total Equity Gross Minority Interest | $1,747,085,000 | $786,742,000 | $666,287,000 | $71,273,000 |
| Stockholders Equity | $1,508,019,000 | $645,938,000 | $522,003,000 | $-211,559,000 |
| Gains Losses Not Affecting Retained Earnings | $-901,378,000 | $-989,118,000 | $-1,402,607,000 | $-1,830,970,000 |
| Other Equity Adjustments | $-901,378,000 | $-989,118,000 | $-1,402,607,000 | $-1,830,970,000 |
| Retained Earnings | $6,534,227,000 | $5,417,139,000 | $4,324,187,000 | $2,977,646,000 |
| Other | ||||
| Treasury Shares Number | $103,464,190 | $101,225,813 | $94,008,158 | $86,496,673 |
| Ordinary Shares Number | $193,937,673 | $194,943,968 | $200,814,804 | $206,203,817 |
| Share Issued | $297,401,863 | $296,169,781 | $294,822,962 | $292,700,490 |
| Tangible Book Value | $-15,942,682,000 | $-12,673,135,000 | $-13,483,897,000 | $-13,048,182,000 |
| Invested Capital | $9,168,792,000 | $5,034,014,000 | $5,309,460,000 | $5,491,274,000 |
| Working Capital | $-5,581,466,000 | $-6,559,240,000 | $-6,032,372,000 | $-3,888,197,000 |
| Total Capitalization | $9,051,007,000 | $4,457,683,000 | $4,668,116,000 | $4,420,801,000 |
| Minority Interest | $239,066,000 | $140,804,000 | $144,284,000 | $282,832,000 |
| Treasury Stock | $10,332,106,000 | $9,815,835,000 | $8,247,103,000 | $7,019,895,000 |
| Additional Paid In Capital | $6,204,302,000 | $6,030,790,000 | $5,844,578,000 | $5,658,733,000 |
| Capital Stock | $2,974,000 | $2,962,000 | $2,948,000 | $2,927,000 |
| Common Stock | $2,974,000 | $2,962,000 | $2,948,000 | $2,927,000 |
| Non Current Accrued Expenses | $3,881,283,000 | $4,296,902,000 | $5,061,795,000 | $5,461,758,000 |
| Current Accrued Expenses | $2,982,993,000 | $2,758,560,000 | $2,353,817,000 | $2,214,592,000 |
| Goodwill | $13,676,520,000 | $9,318,027,000 | $9,574,117,000 | $8,503,886,000 |
| Net PPE | $2,539,076,000 | $2,181,410,000 | $2,135,171,000 | $2,135,003,000 |
| Accumulated Depreciation | $-3,194,242,000 | $-3,033,680,000 | $-2,603,918,000 | $-2,252,345,000 |
| Gross PPE | $5,733,318,000 | $5,215,090,000 | $4,739,089,000 | $4,387,348,000 |
| Machinery Furniture Equipment | $4,479,886,000 | $4,204,268,000 | $3,786,449,000 | $3,424,070,000 |
| Buildings And Improvements | $1,128,433,000 | $893,694,000 | $836,175,000 | $840,852,000 |
| Land And Improvements | $124,999,000 | $117,128,000 | $116,465,000 | $122,426,000 |
| Properties | $0 | $0 | $0 | $0 |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $3,207,139,000 | $2,997,512,000 | $3,452,975,000 | $2,206,770,000 |
| Operating Activities | ||||
| Operating Cash Flow | $3,875,120,000 | $3,484,685,000 | $3,911,334,000 | $2,703,088,000 |
| Cash Flow From Continuing Operating Activities | $3,875,120,000 | $3,484,685,000 | $3,911,334,000 | $2,703,088,000 |
| Operating Gains Losses | $130,309,000 | $16,201,000 | $-40,907,000 | $-61,062,000 |
| Investing Activities | ||||
| Capital Expenditure | $-667,981,000 | $-487,173,000 | $-458,359,000 | $-496,318,000 |
| Investing Cash Flow | $-4,977,293,000 | $-618,096,000 | $-2,602,465,000 | $-368,437,000 |
| Cash Flow From Continuing Investing Activities | $-4,977,293,000 | $-618,096,000 | $-2,602,465,000 | $-368,437,000 |
| Net Other Investing Changes | $-17,440,000 | $-30,722,000 | $9,004,000 | $7,600,000 |
| Capital Expenditure Reported | $-667,981,000 | $-487,173,000 | $-458,359,000 | $-496,318,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-435,471,000 | $-1,491,367,000 | $-1,180,728,000 | $-483,704,000 |
| Financing Cash Flow | $2,249,114,000 | $-2,330,994,000 | $-2,222,278,000 | $-1,752,780,000 |
| Cash Flow From Continuing Financing Activities | $2,249,114,000 | $-2,330,994,000 | $-2,222,278,000 | $-1,752,780,000 |
| Net Other Financing Charges | $-103,135,000 | $-75,847,000 | $-80,692,000 | $-48,198,000 |
| Cash Dividends Paid | $-437,081,000 | $-416,168,000 | $-398,752,000 | $-391,687,000 |
| Common Stock Dividend Paid | $-437,081,000 | $-416,168,000 | $-398,752,000 | $-391,687,000 |
| Net Common Stock Issuance | $-435,471,000 | $-1,491,367,000 | $-1,180,728,000 | $-483,704,000 |
| Issuance Of Capital Stock | - | - | - | $0 |
| Common Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-133,447,038,000 | $-70,776,818,000 | $-78,999,244,000 | $-5,910,897,000 |
| Issuance Of Debt | $136,642,706,000 | $70,391,366,000 | $78,375,986,000 | $4,987,794,000 |
| End Cash Position | $4,394,549,000 | $3,297,880,000 | $2,752,889,000 | $3,593,539,000 |
| Beginning Cash Position | $3,297,880,000 | $2,752,889,000 | $3,593,539,000 | $3,070,128,000 |
| Effect Of Exchange Rate Changes | $-50,272,000 | $9,396,000 | $72,759,000 | $-57,850,000 |
| Changes In Cash | $1,146,941,000 | $535,595,000 | $-913,409,000 | $581,871,000 |
| Proceeds From Stock Option Exercised | $29,133,000 | $37,840,000 | $61,152,000 | $93,912,000 |
| Common Stock Payments | $-435,471,000 | $-1,491,367,000 | $-1,180,728,000 | $-483,704,000 |
| Net Issuance Payments Of Debt | $3,195,668,000 | $-385,452,000 | $-623,258,000 | $-923,103,000 |
| Net Short Term Debt Issuance | $-32,199,000 | $-411,248,000 | $30,548,000 | $160,662,000 |
| Short Term Debt Payments | $-132,166,423,000 | $-70,114,293,000 | $-78,187,891,000 | $-4,671,943,000 |
| Short Term Debt Issuance | $132,134,224,000 | $69,703,045,000 | $78,218,439,000 | $4,832,605,000 |
| Net Long Term Debt Issuance | $3,227,867,000 | $25,796,000 | $-653,806,000 | $-1,083,765,000 |
| Long Term Debt Payments | $-1,280,615,000 | $-662,525,000 | $-811,353,000 | $-1,238,954,000 |
| Long Term Debt Issuance | $4,508,482,000 | $688,321,000 | $157,547,000 | $155,189,000 |
| Net Business Purchase And Sale | $-4,291,872,000 | $-100,201,000 | $-2,153,110,000 | $120,281,000 |
| Purchase Of Business | $-4,291,872,000 | $-100,201,000 | $-2,153,110,000 | $-152,305,000 |
| Change In Working Capital | $35,424,000 | $298,688,000 | $874,542,000 | $-139,662,000 |
| Change In Other Current Liabilities | $-404,102,000 | $-506,155,000 | $-399,963,000 | $-500,195,000 |
| Change In Payables And Accrued Expense | $3,458,509,000 | $4,912,109,000 | $5,958,417,000 | $2,533,413,000 |
| Change In Accrued Expense | $-21,131,000 | $148,533,000 | $51,112,000 | $-457,233,000 |
| Change In Payable | $3,479,640,000 | $4,763,576,000 | $5,907,305,000 | $2,990,646,000 |
| Change In Account Payable | $3,693,364,000 | $4,968,093,000 | $6,103,451,000 | $3,320,725,000 |
| Change In Tax Payable | $-213,724,000 | $-204,517,000 | $-196,146,000 | $-330,079,000 |
| Change In Income Tax Payable | $-213,724,000 | $-204,517,000 | $-196,146,000 | $-330,079,000 |
| Change In Prepaid Assets | $173,857,000 | $156,672,000 | $211,242,000 | $102,708,000 |
| Change In Inventory | $-1,269,429,000 | $-1,479,599,000 | $-2,183,368,000 | $-665,370,000 |
| Change In Receivables | $-1,923,411,000 | $-2,784,339,000 | $-2,711,786,000 | $-1,610,218,000 |
| Changes In Account Receivables | $-1,923,411,000 | $-2,784,339,000 | $-2,711,786,000 | $-1,659,525,000 |
| Other Non Cash Items | $-35,354,000 | $27,173,000 | $304,126,000 | $130,918,000 |
| Stock Based Compensation | $147,963,000 | $147,998,000 | $124,624,000 | $93,400,000 |
| Provisionand Write Offof Assets | $63,306,000 | $40,834,000 | $54,389,000 | $26,053,000 |
| Asset Impairment Charge | $837,378,000 | $418,000,000 | $0 | $80,882,000 |
| Deferred Tax | $59,864,000 | $-102,324,000 | $-118,864,000 | $196,184,000 |
| Deferred Income Tax | $59,864,000 | $-102,324,000 | $-118,864,000 | $196,184,000 |
| Depreciation Amortization Depletion | $1,068,416,000 | $1,118,842,000 | $980,848,000 | $709,835,000 |
| Depreciation And Amortization | $1,068,416,000 | $1,118,842,000 | $980,848,000 | $709,835,000 |
| Amortization Cash Flow | $567,106,000 | $670,642,000 | $562,018,000 | $319,192,000 |
| Amortization Of Intangibles | $567,106,000 | $670,642,000 | $562,018,000 | $319,192,000 |
| Depreciation | $501,310,000 | $448,200,000 | $418,830,000 | $390,643,000 |
| Earnings Losses From Equity Investments | $107,608,000 | $16,201,000 | $-242,000 | $-4,834,000 |
| Gain Loss On Sale Of Business | $22,701,000 | $0 | $-40,665,000 | $-56,228,000 |
| Net Income From Continuing Operations | $1,567,814,000 | $1,519,273,000 | $1,732,576,000 | $1,666,540,000 |
| Other Cash Adjustment Outside Changein Cash | - | $0 | $0 | $-610,000 |
| Sale Of Business | - | $0 | $0 | $272,586,000 |
| Net PPE Purchase And Sale | - | - | - | $6,302,000 |
| Sale Of PPE | - | - | - | $6,302,000 |
Fetched: 2026-06-19